Efficacy of everolimus in second- and third-line therapy for
metastatic renal cell carcinoma: A registry-based analysis

J 2014

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis

BUCHLER, Tomas; Zbyněk BORTLÍČEK; Alexandr POPRACH; Kateřina KUBÁČKOVÁ; Igor KISS et al.

Základní údaje

Originální název

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis

Autoři

BUCHLER, Tomas; Zbyněk BORTLÍČEK; Alexandr POPRACH; Kateřina KUBÁČKOVÁ; Igor KISS; Milada ZEMANOVA; Ondrej FIALA; Ladislav DUŠEK; Rostislav VYZULA a Bohuslav MELICHAR

Vydání

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, New York, ELSEVIER SCIENCE INC. 2014, 1078-1439

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.768

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00076233

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.urolonc.2013.12.007

UT WoS

000338090800009

EID Scopus

2-s2.0-84902530865

Klíčová slova anglicky

Everolimus; mTOR; Renal cell carcinoma; Tyrosine kinase inhibitors; Therapy

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 11. 2014 08:47, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A national renal information system database was used as the data source for the retrospective study. There were 483 patients who received everolimus as the second (n = 350) or the third (n = 112) targeted agent following TKIs. Results: Median progression-free survival (PFS) from the start of everolimus in the second or the third line of targeted therapy was 6.1 months for both subgroups (P = 0.863). Median total PFS from the start of the first targeted agent to progression on the third targeted agent for patients receiving 3 lines of therapy with TKI-TKI-everolimus (n = 112) and TKI-everolimus-TKI (n = 27) sequences was 28.3 months vs. 31.3 months, respectively (P = 0.16), and there was no significant difference in overall survival. PFS on everolimus was associated with PFS on previous TKIs in patients receiving 1 but not 2 previous TKIs. Only 13% of 352 patients starting targeted therapy for mRCC in 2010 had received 3 sequential targeted agents by the data cutoff in March 2013. Conclusion: PFS on everolimus correlated with PFS on TKIs in patients pretreated with 1 but not 2 TKIs. Everolimus can be deferred to the third line without loss of efficacy or increased toxicity. However, only a minority of patients with mRCC starting targeted treatment can be expected to receive third-line therapy.

Citovat

BUCHLER, Tomas; Zbyněk BORTLÍČEK; Alexandr POPRACH; Kateřina KUBÁČKOVÁ; Igor KISS; Milada ZEMANOVA; Ondrej FIALA; Ladislav DUŠEK; Rostislav VYZULA a Bohuslav MELICHAR. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. New York: ELSEVIER SCIENCE INC., 2014, roč. 32, č. 5, s. 569-575. ISSN 1078-1439. Dostupné z: https://doi.org/10.1016/j.urolonc.2013.12.007.

@article{1195775,
   author = {Buchler, Tomas and Bortlíček, Zbyněk and Poprach, Alexandr and Kubáčková, Kateřina and Kiss, Igor and Zemanova, Milada and Fiala, Ondrej and Dušek, Ladislav and Vyzula, Rostislav and Melichar, Bohuslav},
   article_location = {New York},
   article_number = {5},
   doi = {https://doi.org/10.1016/j.urolonc.2013.12.007},
   keywords = {Everolimus; mTOR; Renal cell carcinoma; Tyrosine kinase inhibitors; Therapy},
   language = {eng},
   issn = {1078-1439},
   journal = {UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS},
   title = {Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis},
   volume = {32},
   year = {2014}
}

TY  - JOUR
ID  - 1195775
AU  - Buchler, Tomas - Bortlíček, Zbyněk - Poprach, Alexandr - Kubáčková, Kateřina - Kiss, Igor - Zemanova, Milada - Fiala, Ondrej - Dušek, Ladislav - Vyzula, Rostislav - Melichar, Bohuslav
PY  - 2014
TI  - Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
JF  - UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
VL  - 32
IS  - 5
SP  - 569-575
EP  - 569-575
PB  - ELSEVIER SCIENCE INC.
SN  - 10781439
KW  - Everolimus
KW  - mTOR
KW  - Renal cell carcinoma
KW  - Tyrosine kinase inhibitors
KW  - Therapy
N2  - Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A national renal information system database was used as the data source for the retrospective study. There were 483 patients who received everolimus as the second (n = 350) or the third (n = 112) targeted agent following TKIs. Results: Median progression-free survival (PFS) from the start of everolimus in the second or the third line of targeted therapy was 6.1 months for both subgroups (P = 0.863). Median total PFS from the start of the first targeted agent to progression on the third targeted agent for patients receiving 3 lines of therapy with TKI-TKI-everolimus (n = 112) and TKI-everolimus-TKI (n = 27) sequences was 28.3 months vs. 31.3 months, respectively (P = 0.16), and there was no significant difference in overall survival. PFS on everolimus was associated with PFS on previous TKIs in patients receiving 1 but not 2 previous TKIs. Only 13% of 352 patients starting targeted therapy for mRCC in 2010 had received 3 sequential targeted agents by the data cutoff in March 2013. Conclusion: PFS on everolimus correlated with PFS on TKIs in patients pretreated with 1 but not 2 TKIs. Everolimus can be deferred to the third line without loss of efficacy or increased toxicity. However, only a minority of patients with mRCC starting targeted treatment can be expected to receive third-line therapy.
ER  -

BUCHLER, Tomas; Zbyněk BORTLÍČEK; Alexandr POPRACH; Kateřina KUBÁČKOVÁ; Igor KISS; Milada ZEMANOVA; Ondrej FIALA; Ladislav DUŠEK; Rostislav VYZULA a Bohuslav MELICHAR. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. \textit{UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}. New York: ELSEVIER SCIENCE INC., 2014, roč.~32, č.~5, s.~569-575. ISSN~1078-1439. Dostupné z: https://doi.org/10.1016/j.urolonc.2013.12.007.

Přehled o publikaci